Liquidia Technologies Inc (NASDAQ:LQDA) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,420,000 shares, a growth of 43.3% from the June 15th total of 990,600 shares. Currently, 9.5% of the company’s stock are sold short. Based on an average daily trading volume, of 209,800 shares, the short-interest ratio is presently 6.8 days.
In other news, major shareholder Eshelman Ventures, Llc acquired 1,875,000 shares of Liquidia Technologies stock in a transaction dated Thursday, July 2nd. The stock was bought at an average cost of $8.00 per share, with a total value of $15,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of LQDA. Marshall Wace LLP bought a new position in Liquidia Technologies during the 1st quarter worth $32,000. State Street Corp increased its stake in Liquidia Technologies by 7.3% during the 4th quarter. State Street Corp now owns 185,015 shares of the company’s stock worth $791,000 after acquiring an additional 12,553 shares during the period. Barclays PLC boosted its holdings in shares of Liquidia Technologies by 95.7% in the 4th quarter. Barclays PLC now owns 13,426 shares of the company’s stock valued at $57,000 after purchasing an additional 6,564 shares in the last quarter. UBS Group AG boosted its holdings in shares of Liquidia Technologies by 95.6% in the 4th quarter. UBS Group AG now owns 20,118 shares of the company’s stock valued at $86,000 after purchasing an additional 9,835 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its holdings in shares of Liquidia Technologies by 4.0% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,658,485 shares of the company’s stock valued at $7,090,000 after purchasing an additional 63,202 shares in the last quarter. Hedge funds and other institutional investors own 44.89% of the company’s stock.
LQDA has been the subject of several recent research reports. BidaskClub raised Liquidia Technologies from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 23rd. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Liquidia Technologies in a research report on Wednesday, March 11th. Wedbush reissued a “buy” rating and set a $41.00 price target on shares of Liquidia Technologies in a research report on Friday, June 12th. Cowen reissued an “outperform” rating and set a $40.00 price target on shares of Liquidia Technologies in a research report on Wednesday, May 6th. Finally, ValuEngine cut Liquidia Technologies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 14th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Liquidia Technologies has a consensus rating of “Buy” and an average price target of $29.88.
Shares of LQDA traded down $0.49 during mid-day trading on Friday, reaching $7.79. The company’s stock had a trading volume of 1,062,041 shares, compared to its average volume of 519,146. Liquidia Technologies has a 1-year low of $2.65 and a 1-year high of $12.10. The stock has a market cap of $221.02 million, a P/E ratio of -3.42 and a beta of 0.82. The business has a 50-day simple moving average of $8.83 and a two-hundred day simple moving average of $6.04. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.69.
Liquidia Technologies (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.01. Research analysts anticipate that Liquidia Technologies will post -2.4 EPS for the current year.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
Featured Story: What is a capital gain?
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.